ATE366120T1 - Hocheffizientes gewebespezifisches system zur bereitstellung von verbindungen unter verwendung eines streptavidin-protein a fusionsproteins - Google Patents

Hocheffizientes gewebespezifisches system zur bereitstellung von verbindungen unter verwendung eines streptavidin-protein a fusionsproteins

Info

Publication number
ATE366120T1
ATE366120T1 AT96941471T AT96941471T ATE366120T1 AT E366120 T1 ATE366120 T1 AT E366120T1 AT 96941471 T AT96941471 T AT 96941471T AT 96941471 T AT96941471 T AT 96941471T AT E366120 T1 ATE366120 T1 AT E366120T1
Authority
AT
Austria
Prior art keywords
protein
highly efficient
streptavidin
fusion protein
specific system
Prior art date
Application number
AT96941471T
Other languages
English (en)
Inventor
Daniel Meruelo
Kouichi Ohno
Brandi Levin
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Application granted granted Critical
Publication of ATE366120T1 publication Critical patent/ATE366120T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
AT96941471T 1995-11-30 1996-11-26 Hocheffizientes gewebespezifisches system zur bereitstellung von verbindungen unter verwendung eines streptavidin-protein a fusionsproteins ATE366120T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/566,421 US6497881B1 (en) 1995-11-30 1995-11-30 High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein

Publications (1)

Publication Number Publication Date
ATE366120T1 true ATE366120T1 (de) 2007-07-15

Family

ID=24262817

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96941471T ATE366120T1 (de) 1995-11-30 1996-11-26 Hocheffizientes gewebespezifisches system zur bereitstellung von verbindungen unter verwendung eines streptavidin-protein a fusionsproteins

Country Status (10)

Country Link
US (3) US6497881B1 (de)
EP (1) EP0868435B1 (de)
JP (1) JP4124482B2 (de)
AT (1) ATE366120T1 (de)
AU (1) AU1060397A (de)
DE (1) DE69637154T2 (de)
DK (1) DK0868435T3 (de)
ES (1) ES2289754T3 (de)
PT (1) PT868435E (de)
WO (1) WO1997019957A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6497881B1 (en) * 1995-11-30 2002-12-24 New York University High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
DE19735105A1 (de) * 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen
JP2002504328A (ja) 1998-02-23 2002-02-12 アーク・セラピューティックス・リミテッド ビオチン結合性レセプター分子
US6380364B1 (en) * 1998-11-23 2002-04-30 Loyola University Of Chicago Chimeric biotin-binding papillomavirus protein
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
AU5597500A (en) * 1999-06-07 2000-12-28 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
AU6607100A (en) * 1999-07-23 2001-02-13 Regents Of The University Of California, The Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
CA2490542C (en) 2002-05-23 2013-07-16 Mark I. Greene Fas peptide mimetics and uses thereof
EP1718323B1 (de) * 2004-02-20 2011-12-07 The Trustees of The University of Pennsylvania Bindende peptidomimetika und deren verwendungen
US20080254551A1 (en) * 2004-12-30 2008-10-16 Achsel Tilmann Immunoprecipitaion-Based Method to Purify and Characterise Biological Macromolecular Complexes
DK2220107T3 (en) 2007-11-12 2017-02-13 Chreto Aps Double affinity polypeptide for purification
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
CN107108750A (zh) * 2014-10-28 2017-08-29 默克专利股份公司 细胞表面上非共价含Fc结构域的蛋白质展示的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
GB8813527D0 (en) * 1988-06-08 1988-07-13 Glennie M J Bispecific antibodies
US5407653A (en) * 1991-06-26 1995-04-18 Brigham And Women's Hospital Evaluation of the multidrug resistance phenotype
US5328985A (en) 1991-07-12 1994-07-12 The Regents Of The University Of California Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system
PT627940E (pt) * 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
GB9300686D0 (en) 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
CA2224907A1 (en) 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
US6497881B1 (en) * 1995-11-30 2002-12-24 New York University High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein

Also Published As

Publication number Publication date
DE69637154T2 (de) 2008-03-13
JP4124482B2 (ja) 2008-07-23
JP2000502885A (ja) 2000-03-14
EP0868435A1 (de) 1998-10-07
EP0868435A4 (de) 2001-04-04
ES2289754T3 (es) 2008-02-01
EP0868435B1 (de) 2007-07-04
US20030113337A1 (en) 2003-06-19
US6497881B1 (en) 2002-12-24
WO1997019957A1 (en) 1997-06-05
AU1060397A (en) 1997-06-19
DK0868435T3 (da) 2007-11-05
DE69637154D1 (de) 2007-08-16
US20090098148A1 (en) 2009-04-16
PT868435E (pt) 2007-10-01

Similar Documents

Publication Publication Date Title
ATE366120T1 (de) Hocheffizientes gewebespezifisches system zur bereitstellung von verbindungen unter verwendung eines streptavidin-protein a fusionsproteins
ATE187176T1 (de) Verfahren zur herstellung von heterologen bispezifischen antikörpern
DE69637867D1 (de) Verfahren zur Kontrollierung der Sialylierung von durch Säugetierzellkultur hergestellten Proteinen
ATE369384T1 (de) Expression und export von interferon-alpha proteinen als fc fusionsproteine
DE69836092D1 (de) Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
ATE473754T1 (de) Verfahren zur manipulation der zelldifferenzierung
MX9709442A (es) Metodo y composiciones para la inhibicion de interacciones entre proteina adaptadora y tirosinquinasa.
ATE352617T1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
ATE414162T1 (de) Verfahren und materialien zur herstellung von glucosamin
DE69332829D1 (de) Enzymatisches verfahren dass enzyme die an der zellwand einer eukaryontischen mikrobiellen zelle durch schaffung eines fusionsproteins immobilisiert wurden verwendet.
DE69635186D1 (de) Verfahren zur herstellung von häm-enthaltende proteine durch pflanzenzellen, hergestellte proteine und diese enthaltende produkten
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
DE69735264D1 (de) Gefrierschutzproteine aus choristoneura sp., gene und verfahren zu ihrer verwendung
ATE279441T1 (de) Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
ATE474922T1 (de) Fluoreszenzproteine aus copepoda-spezies und verfahren zur verwendung davon
DE69332471D1 (de) Verfahren zur herstellung modifizierten proteine
MX9603266A (es) Genes de timocina de mamiferos.
ATE522604T1 (de) Verfahren zur herstellung von proteinen durch elektropulsierung
DE60233347D1 (de) Schnellreifende fluoreszierende proteine und verfahren zu deren anwendung
DE69739880D1 (de) NUKLEINSÄURELIGANDEN MIT HOHER AFFINITÄT FÜR DAS C1q PROTEIN DES KOMPLEMENTSYSTEMS
DE60040789D1 (de) Verfahren zur aufreinigung heterologer proteine
DE69930118D1 (de) Verfahren zur herstellung von proteinen in transformierten hefezellen
DE60223937D1 (de) Nukleinsäuren kodierend miteinander verbundene chromo/fluoreszenzdomänen und verfahren zu ihrer verwendung
ATE307201T1 (de) Srcr domäne-enthaltendes protein

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee